Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 16/20 | 1.00 |
| ▸ | VEGFA | P15692 | 11/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | ARNT | P27540 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16560911 | 1.00 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL16560907 | 1.00 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL16560855 | 1.00 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18078513 | 0.91 | EPAS1 (0.83) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18078560 | 0.91 | EPAS1 (0.83) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18036957 | 0.90 | EPAS1 (0.82) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18036956 | 0.90 | EPAS1 (0.82) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL16560905 | 0.90 | VEGFA (1.00) | EPAS1VEGFA | |
| SCHEMBL16556231 | 0.90 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL16560913 | 0.90 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544403-B2 | Methods to treat mitochondrial-associated dysfunctions or diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2026-02-10 | — | — | US | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| WO-2025106877-A1 | INHALED HYPOXIA AND SMALL MOLECULE FORMS OF HYPOXIA AS NOVEL ANTICANCER AGENTS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2025-05-22 | — | — | WO | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| CN-119365486-A | EPO receptor agonists and antagonists | 免疫先锋股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| EP-4490187-A2 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | Immunedge, Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| EP-3713644-B1 | COMPOSITIONS AND METHODS FOR MODULATING HIF-2A TO IMPROVE MUSCLE GENERATION AND REPAIR | UNIV GEORGIA (US) | 2024-08-07 | — | — | EP | claimed |
| CN-107979786-B | Support stereo set of many USB flash discs and many bluetooth broadcast | 东莞市美之尊电子科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240254179-A1 | Targeting Nuclear Speckles and DNA Speckle Association | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | claimed |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-07-23 | — | — | US | claimed |
| CN-221283333-U | Audio signal frequency compression system | 广州长嘉电子有限公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2024050548-A9 | COMPACT PROMOTERS FOR TARGETING HYPOXIA INDUCED GENES | HUNTERIAN MEDICINE LLC (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024050548-A2 | COMPACT PROMOTERS FOR TARGETING HYPOXIA INDUCED GENES | HUNTERIAN MEDICINE LLC (US) | 2024-03-07 | — | — | WO | claimed |
| WO-2023172989-A2 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE, INC. (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230104671-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOMYOPATHY AND HEART FAILURE | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2023-04-06 | — | — | US | claimed |
| WO-2022229932-A1 | HYPOXIA INDUCIBLE FACTOR (HIF) INHIBITORS FOR TREATMENT OF ATROPHY ASSOCIATED WITH RETINAL HYPOXIA | STEFANSSON EINAR (IS) | 2022-11-03 | — | — | WO | claimed |
| US-20220096541-A1 | METHODS TO TREAT MITOCHONDRIAL-ASSOCIATED DYSFUNCTIONS OR DISEASES | THE GENERAL HOSPITAL CORPORATION | 2022-03-31 | — | — | US | claimed |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | IMMUNEDGE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-216217441-U | Special reverberation version wireless receiver of musical instrument | 恩平市宏博音响科技有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20220096541-A1 | METHODS TO TREAT MITOCHONDRIAL-ASSOCIATED DYSFUNCTIONS OR DISEASES | THE GENERAL HOSPITAL CORPORATION | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096541-A1 | METHODS TO TREAT MITOCHONDRIAL-ASSOCIATED DYSFUNCTIONS OR DISEASES | SHMT2, HAGH, TUFM | EPAS1 650/4885VEGFA 3181/4885CYP2C9 3474/4885 |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | EPAS1 158/4885VEGFA 222/4885CYP2C9 4421/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | EPAS1 3996/4885VEGFA 3507/4885CYP2C9 791/4885 |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | EPOR, MPL, CSF3R | EPAS1 720/4885VEGFA 175/4885CYP2C9 4284/4885 |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | HIF1A, HIF1AN, MYLK2 | EPAS1 39/4885VEGFA 523/4885CYP2C9 4830/4885 |
| US-12544403-B2 | Methods to treat mitochondrial-associated dysfunctions or diseases | TFAM, FH, HSPA9 | EPAS1 327/4885VEGFA 1330/4885CYP2C9 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.